• Pharma

     

    Digitally-enabled pharmacotherapy, theragnostics, and mental health endpoints.

     

    The greatest challenges facing the pharmaceutical industry today include changing patient expectations, increased self-medication, difficulties in identifying novel medicines for incurable diseases, high payer scrutiny of pharma-economic performance, the trend for governments to favour prevention over treatment, and access to emerging markets. Partnering with MI helps turn these challenges into opportunities.

     

    Patient Testimonials

     

    "…it was helping me get through my post cancer treatments and my cancer that has been a very very rough journey."

    Breast cancer survivor (double mastectomy)

     

     

    "... this [digital therapeutic] forced me to block out the world and say okay, this moment is mine right now, and I'm going to enjoy this moment for myself."

    Testicular cancer survivor (chemotherapy)

     

    "…I felt like it was an actual meditation – like they were actually there with me."

    Kidney cancer survivor (immunotherapy)

     

     

  • What we offer

    ✓ Delivery of clinical resilience training at scale

    ✓ Objective data insights and resilience content preferences

    ✓ Full backend integration for policyholder verification

    ✓ A digital biomarker SDK and psychotherapy library API that plugs into existing systems
    broken image

    Rx + DTx Pairing

    Improve efficacy & patient experience

     

    Accelerate market access & reimbursement

    broken image

    Standalone DTx

    Generate compound-agnostic revenue

     

    Access actionable patient data

     

    broken image

    Clinical Endpoints

    Capture objective biometrics remotely

     

    Augment mental wellbeing assessment

  • Certifications

    Mobio Interactive’s digital therapeutic platform “AmDTx” is DCB 0129 and ISO 27001 certified; GDPR-, HIPAA- and PHIPA-compliant; and undergoing certification for CE MDR Class IIa, ISO 13485, ISO 9000 and ISO 82304-2.

    Validating the accuracy of our digital biomarkers and the efficacy of our digital theragnostic platform, AmDTx, Mobio has published 19 peer-reviewed papers to date from 17 completed clinical studies.

    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More